Ground-breaking work by university experts in Tennessee, Texas and Swansea University is helping develop a better understanding of the growing threat posed by antifungal drug resistance.
Invasive aspergillosis is a devastating disease caused by breathing in small airborne spores of the fungus Aspergillus fumigatus and it is a condition where drug resistance has been encountered.
In a healthy person these spores are destroyed by the body's immune system but in those with a weakened immune system -- such as following organ transplantation or in someone with a lung condition such as asthma or cystic fibrosis -- they can trigger a range of problems including infections.
Every year aspergillosis leads to more than 200,000 life-threatening infections and increasingly resistance to vital antifungal drug treatments makes those infections harder to treat.
National Institutes of Health funding supported a collaboration between the University of Tennessee, the University of Texas and Swansea University as part of a $2 million, five-year research program. This support enabled investigation of resistance to the triazole class of antifungal drugs used for treating the disease
A new paper, published in the American Microbiology Society journal mBio, reveals how researchers have been able to identify a previously uncharacterised genetic mutation in clinical isolates that leads to resistance.
Professor Jarrod Fortwendel, from the University of Tennessee, said, "As with bacteria, antifungal drug resistance is a real challenge facing medicine. Understanding how the fungus becomes drug resistant is important for designing changes in therapy to overcome aspergillosis."
Professor Dave Rogers, also from the University of Tennessee, added, "It is very important that the research continues and we find out more about why it is happening and how we can tackle it for the future."
Swansea University's professor Steve Kelly, whose experience researching the field of antifungal resistance dates back to 1984, described the findings as a real breakthrough. "This paper is the result of a lot of hard work and we are delighted to now be able to publish our findings."
Source: Swansea University
Reflecting on the US Withdrawal from the World Health Organization
January 21st 2025An infection preventionist reels from the US exit from WHO, writing that it disrupts global health efforts, weakens infection control, and lacks research funding and support for low-income nations dependent on WHO for health care resources.
Infections Do Not Recognize International Borders: The Potential Impact of US Withdrawal From WHO
January 21st 2025The US withdrawal from WHO jeopardizes infection prevention, research funding, and global collaboration, disproportionately impacting low-income nations reliant on WHO support for equitable health care advancements.
Infection Intel:EvaClean Expands Global Reach With Microsplitting Partnership
January 20th 2025EvaClean partners with Microsplitting Ltd. to distribute its advanced disinfection systems and absorbents, revolutionizing infection prevention across health care, education, hospitality, and industrial sectors worldwide.